In a weaker economy, households tend to keep paying internet bills but steer clear of brand-name goods. What about obesity treatments, which can cost $1,000 a month? The jury is out, but weaker US consumption growth alongside a price war seems bad for Eli Lilly and Novo Nordisk.
